Clinical Trial: Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter, Randomized, Double-blind, Valacyclovir Hydrochloride-controlled, Parallel-group, Comparative S
Brief Summary: To investigate the efficacy and safety of three different doses of ASP2151, as compared to valacyclovir hydrochloride in subjects with herpes zoster, and to determine the recommended clinical dose.
Detailed Summary:
Sponsor: Astellas Pharma Inc
Current Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir in subjects with Herpes Zoster [ Time Frame: 3 months ]
Original Primary Outcome: To compare the efficacy and safety of ASP2151 with valacyclovir in subjects with Herpes Zoster
Current Secondary Outcome: Improvement of cutaneous symptoms and pain [ Time Frame: 3 months ]
Original Secondary Outcome: Improvement of cutaneous symptoms and pain
Information By: Astellas Pharma Inc
Dates:
Date Received: June 15, 2007
Date Started: August 2007
Date Completion:
Last Updated: December 19, 2011
Last Verified: December 2011